On April 11, 2019, AriBio Co., Ltd. announced the first patient dosing
in their Phase 2 study of AR1001 for Alzheimer’s disease.
SAN DIEGO–(BUSINESS WIRE)–AriBio announced the initiation of a Phase 2 study to evaluate the
safety and efficacy of AR1001 in patients with mild to moderate
Alzheimer’s disease. “Based on the established safety profile of AR1001
and the promising preclinical data, we are hopeful to see a clinically
meaningful outcome from this Phase 2 study. As the demand for
therapeutic advancement for Alzheimer’s disease and other
neurodegenerative diseases rapidly grows, we are strongly committed to
expanding our AR1001 program with additional indications and advancing
several back-up candidates in our pipeline,” said James Rock, Senior
Vice President of Global Operations.
About the AR1001 and Phase 2 study for Alzheimer’s disease
AR1001 is a multi-target oral drug for the treatment of Alzheimer’s
Disease and is expected to not only increase the removal of toxic beta
amyloid oligomers in circulation, but also inhibit neuronal cell death
and restore synaptic loss caused by Alzheimer’s disease.
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized,
Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week
Treatment of AR1001 in Patients with Mild to Moderate Alzheimer’s
Disease. The study aims to assess the safety and efficacy of AR1001 in
slowing the progression of Alzheimer’s disease through various cognitive
and functional assessments and biomarker analysis. Enrollment is
expected to be completed in Q4 2019, and details of the clinical trial
are available at ClinicalTrial.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea
that focuses on targeting diseases with unmet medical needs. There are
currently three main areas of research: Alzheimer’s disease (AR1001),
Sepsis (AR1003), and Obesity (AR1008). Earlier in 2018, AriBio Co., Ltd.
established its US office in San Diego, CA, to efficiently manage
regulatory affairs and clinical operations. AriBio also develops a
variety of functional foods, bio cosmetics, and functional water
products with the hopes of improving the quality of life.
Contacts
Fred Kim
Clinical Trials Manager
fredkim@aribiousa.com